EndoPredict outperforms Oncotype Dx in predicting the risk breast cancer recurrence

EndoPredict outperforms Oncotype Dx in predicting the risk breast cancer recurrence


SALT LAKE CITY, Utah, Dec. 9, 2016 - Myriad Genetics, Inc. , a leader in molecular diagnostics and personalized medicine, today announced results of a large head-to-head study comparing the efficacy of six tests used to predict the recurrence of breast cancer. A key finding was that EndoPredict , a second-generation test, was superior to Oncotype Dx , a first-generation test, in predicting the long-term recurrence of breast cancer.



from Biotech News